Reduction of adverse effects by a mushroom product, active hexose correlated compound (AHCC) in patients with advanced cancer during chemotherapy-the significance of the levels of HHV-6 DNA in saliva as a surrogate biomarker during chemotherapy

Nutrition and Cancer

Volumn 66, Issue 3, 2014, Pages 377-382

  Ito, Toshinori ^a   Urushima, Hayato ^a   Sakaue, Miki ^a   Yukawa, Sayoko ^a   Honda, Hatsumi ^a   Hirai, Kei ^b   Igura, Takumi ^a   Hayashi, Noriyuki ^a   Maeda, Kazuhisa ^a   Kitagawa, Toru ^a   Kondo, Kazuhiro ^c  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE HEXOSE CORRELATED COMPOUND; ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; FOLINATE CALCIUM; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; NATURAL PRODUCT; PACLITAXEL; UFT; UNCLASSIFIED DRUG; VIRUS DNA; BIOLOGICAL MARKER; POLYSACCHARIDE;

ADULT; ADVANCED CANCER; ADVERSE DRUG REACTION; AGED; ARTICLE; BLOOD EXAMINATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COLON CANCER; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEMALE; HUMAN; HUMAN HERPESVIRUS 6; LIVER TOXICITY; LUNG CANCER; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; QUESTIONNAIRE; SALIVA ANALYSIS; SCORING SYSTEM; THROMBOCYTOPENIA; BLOOD; CLINICAL TRIAL; GENETICS; NEOPLASMS; SALIVA; TREATMENT OUTCOME; VIROLOGY;

BASIDIOMYCOTA; HUMAN HERPESVIRUS 6;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; DNA, VIRAL; FEMALE; HERPESVIRUS 6, HUMAN; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POLYSACCHARIDES; QUALITY OF LIFE; QUESTIONNAIRES; SALIVA; TREATMENT OUTCOME;

EID: 84897423109     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2014.884232     Document Type: Article

References (26)

1. Ye SF, Ichimura K, Wakame K, and Ohe M: Suppressive effects of active hexose correlated compound on the increased activity of hepatic and renal ornithine decarboxylase induced by oxidative stress. Life Sci 74, 593-602, 2003. (Pubitemid 37410350)
2. Daddaoua A, Martinez-Plata E, Lopez-Posadas R, Vieites JM, Gonzalez M, et al.: Active hexose correlated compound acts as a prebiotic and is antiinflammatory in rats with hapten-induced colitis. J Nutr 137, 1222-1228, 2007. (Pubitemid 46701915)
3. Matsushita K, Kuramitsu Y, Ohiro Y, Obara M, Kobayashi M, et al.:Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma. Anticancer Drugs 9, 343-350, 1998. (Pubitemid 28241824)
4. Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, et al. : Improved prognosis of postoperative hepatocellular carcinoma patients treated with functional foods. J Hepatol 37, 78-86, 2002. (Pubitemid 34713058)
5. Aviles H, O'Donnell P, Orshal J, Fujii H, Sun B, et al.: Active hexose correlated compound activates immune function to decrease bacterial load in a murine model of intramuscular infection. Am J Surg 195, 537-545, 2008. (Pubitemid 351417481)
6. Aviles H, Belay T, Fountain K, Vance M, Sonnenfeld G, et al.: AHCC enhances resistance to Klebsiella pneumoniae infection in mice in the hindlimb-unloading model of spaceflight conditions. J Appl Physiol 95, 491-496, 2003. (Pubitemid 36944268)
7. Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, et al.: Identi-fication of human herpesvirus 6 as a causal agent for exanthema subitum. Lancet 331, 1065-1067, 1988.
8. Tanaka M, Shigihara Y, Funakura M, Kanai E, and Watanabe Y: Fatigueassociated alterations of cognitive function and electroencephalographic power densities. PLoS ONE 7(4): e34774, 2012. doi:10. 1371/journal.
9. Singh N and Carrigan DR: Human herpesvirus-6 in transplantation : an emerging pathogen. Ann Intern Med 124, 1065-1071, 1996.
10. Zerr DM, Boeckh M, Delaney C, Martin PJ, Xie Hu, et al.: HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation. Biol Blood Marrow Transplant 18, 1700-1708, 2012. doi:10.1016/j.bbmt.2012.05.012
11. Miura T, Kitadate K, Nishioka H, andWakame K. Basic and clinical studies on active hexose correlated compound. In: Biotechnology in Functional Foods and Nutraceuticals, Bagchi D, Lau FC, and Ghosh DK, (eds.). New York: CRC Press, pp. 51-60, 2010.
12. Fujii H, Nishioka N, Simon RR, Kaur R, Lynch B, et al.: Genotoxicity and subchronic toxicity evaluation of active hexose correlated compound (AHCC). Regul Toxicol Pharm 59, 237-250, 2011. doi:10. 1016/j.yrtph.2010.10.006
13. Shah SK, Walker PA, Moore-Olufemi SD, Sundaresant A, Kulkami AD, et al.: An evidence-based review of a Lentinula edodes mushroom extract as complementary therapy in surgical oncology patient. J Parenter Enteral Nutr 35, 449-458, 2011.
14. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, et al.: The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer 85, 365-376, 1993. (Pubitemid 23073154)
15. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, et al.: Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 328, 246-252, 1993. (Pubitemid 23035311)
16. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280, 1569-1575, 1998. (Pubitemid 28520643)
17. In:AbramsDI andWeil AT (eds.): Integrative Oncology.OxfordUniversity Press, New York, 2009.
18. Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, et al.:Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol 23, 2645-2654, 2005. (Pubitemid 46179453)
19. Mach CM, Fujii H, Wakame K, and Smith J: Evaluation of active hexose correlated compound hepatic metabolism and potential for drug interactions with chemotherapy agents. J Soc Integr Oncol 6, 105-109, 2008.
20. Kondo K, Kondo T, Okuno T, Takahashi M, and Yamanishi K: Latent human herpes virus 6 of human monocytes/macrophages. J Gen Virol 72, 1401-1408, 1991.
21. Kondo K, Nagafuji H, Hata A, Tomomori C, and Yamanishi K: Association of human herpes virus 6 infection of the central nervous system with recurrence of febrile convulsions. J Infect Dis 167, 1197-1200, 1993. (Pubitemid 23115615)
22. Okuno T, Takahashi K, Balachandra K, Shiraki K, Yamanishi K, et al.: Seroepidemiology of human herpesvirus 6 infection in normal children and adults. Clin Microbiol 27, 651-653, 1989. (Pubitemid 19098097)
23. Braun DK, Dominguez G, and Pellett PE: Human herpesvirus 6. Clin Microbiol Rev 10, 521-567, 1997. (Pubitemid 27359264)
24. Cohrs RJ and Gilden DH: Human herpes virus latency. Brain Pathol 11, 465-474, 2001.
25. Cameron B, Flamand L, Juwana H, Middeldorp J, Naing Z, et al.: Serological and virological investigation of the role of herpes viruses EBV, CMV and HHV-6 in post-infective chronic fatigue. J Med Virol 82, 1684-1688, 2010.
26. Sun B, Wakame K, Sato E, Nishioka H, Aruoma OI, et al.: The effect of active hexose correlated compound in modulating cytosine arabinosideinduced hair loss, and 6-mercaptopurine-and methotrexate-induced liver injury in rodents. Cancer Epidemiology 33, 293-299, 2009.